L-159282 (MK 996)
(Synonyms: MK 996) 目录号 : GC32569
L-159282 (MK 996) 是一种高效的口服活性非肽血管紧张素 II 受体拮抗剂，具有抗高血压活性。
Cas No.:157263-00-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
L-159282 is a highly potent, orally active, nonpeptide angiotensin II receptor antagonist, with anti-hypertensive activity.
In the anesthetized chimpanzee, L-159282 (1 mg/kg, iv) produces 100% inhibition of the AII pressor response and is still active (52%) at 24 h. In aortic coarcted (high renin) rats, L-159282 (3 mg/kg, p.o.) reduces blood pressure to normotensive (< 120 mm Hg) levels without reflex tachycardia. This dose of L-159282 reduces blood pressure to approximately the same level as both losartan (3 mg/kg, p.o.) and enalapril (3 mg/kg, p.o.) in this model[1].
[1]. Kivlighn SD, et al. In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996. Am J Hypertens. 1995 Jan;8(1):58-66.
| Cas No. | 157263-00-8 | SDF | |
| 别名 | MK 996 | ||
| Canonical SMILES | O=C(NS(=O)(C1=CC=CC=C1C2=CC=C(CN3C(CC)=NC4=C(C)C=C(C)N=C43)C=C2)=O)C5=CC=CC=C5 | ||
| 分子式 | C30H28N4O3S | 分子量 | 524.63 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9061 mL | 9.5305 mL | 19.0611 mL |
| 5 mM | 0.3812 mL | 1.9061 mL | 3.8122 mL |
| 10 mM | 0.1906 mL | 0.9531 mL | 1.9061 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Can Malawi's poor afford free tuberculosis services? Patient and household costs associated with a tuberculosis diagnosis in Lilongwe
Bull World Health Organ 2007 Aug;85(8):580-5.PMID:17768515DOI:10.2471/blt.06.033167.
Objective: To assess the relative costs of accessing a TB diagnosis for the poor and for women in urban Lilongwe, Malawi, a setting where public health services are accessible within 6 kilometers and provided free of charge. Methods: Patient and household direct and opportunity costs were assessed from a survey of 179 TB patients, systematically sampled from all public and mission health facilities in Lilongwe. Poverty status was determined from the 1998 Malawi Integrated Household Survey (MIHS). Findings: On average, patients spent US$ 13 (MK 996 or 18 days' income) and lost 22 days from work while accessing a TB diagnosis. For non-poor patients, the total costs amounted to 129% of total monthly income, or 184% after food expenditures. For the poor, this cost rose to 248% of monthly income or 574% after food. When a woman or when the poor are sick, the opportunity costs faced by their households are greater. Conclusion: Patient and household costs of TB diagnosis are prohibitively high even where services are provided free of charge. In scaling up TB services to reach the Millennium Development Goals, there is an urgent need to identify strategies for diagnosing TB that are cost-effective for the poor and their households.